Comparative Pharmacology
Head-to-head clinical analysis: SYNALAR versus TARPEYO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNALAR versus TARPEYO.
SYNALAR vs TARPEYO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
TARPEYO (budesonide) is a corticosteroid with anti-inflammatory activity. It acts by binding to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines and immune cell activation, thereby reducing proteinuria in IgA nephropathy.
Apply a thin layer to affected area twice daily. Max 60 g/week.
16 mg/kg intravenously once daily on Days 1-5 of each 28-day cycle.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (topical use); 3-4 hours (systemic absorption after topical application to large areas or occluded skin). Clinical context: short half-life allows once- or twice-daily dosing.
Terminal elimination half-life is approximately 27.3 hours (range 21-36 hours) in patients with IgA nephropathy. This supports once-weekly subcutaneous dosing without dose adjustment over the dosing interval.
Renal: <1% as unchanged drug; biliary/fecal: minimal; primarily hepatic metabolism with metabolites excreted renally.
Primarily hepatic metabolism, with <1% excreted unchanged in urine and <1% in feces. Elimination is predominantly via biliary excretion of metabolites into feces, accounting for >90% of total clearance.
Category C
Category C
Corticosteroid
Corticosteroid